Yankees Score with ...
Health Care: Drugs
Venaxis Inc (APPY: NASDAQ)
$1.30 -0.06 | -4.41%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 10.98M | 2.97M | 8.91M | 13.37M |
| Receivables | 0.00 | 35.02K | 73.18K | 47.96K |
| Inventories | 0.00 | 0.00 | 17.13K | 339.55K |
| Other Current Assets | 387.48K | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 12.53M | 4.32M | 12.31M | 14.43M |
| Property, Plant & Equipment, Gross | 5.56M | 5.52M | 5.52M | 5.33M |
| Accumulated Depreciation & Depletion | 3.08M | 2.73M | 2.41M | 2.02M |
| Property, Plant & Equipment, Net | 2.48M | 2.80M | 3.11M | 3.31M |
| Intangibles | 1.21M | 1.21M | 1.34M | 1.23M |
| Other Non-Current Assets | 3.96K | 9.66K | 15.37K | 21.08K |
| Total Non-Current Assets | 4.09M | 4.41M | 4.85M | 4.95M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 16.61M | 8.73M | 17.16M | 19.38M |
| Accounts Payable | 613.92K | 581.71K | 1.13M | 1.55M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 4.08M | 2.07M | 2.73M | 3.27M |
| Long Term Debt | 763.13K | 2.83M | 2.55M | 2.66M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 1.08M | 0.00 | 633.64K | 634.14K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 1.84M | 2.83M | 3.18M | 3.29M |
| Total Liabilities | 5.92M | 4.90M | 5.91M | 6.56M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 10.69M | 3.83M | 11.25M | 12.81M |
| Common Par | 84.92M | 0.00 | 0.00 | 0.00 |
| Additional Paid In Capital | 0.00 | 68.85M | 66.05M | 54.28M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -74.23M | -65.02M | -54.81M | -41.47M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 11.45M | 6.66M | 13.79M | 15.47M |
| Total Equity | 10.69M | 3.83M | 11.25M | 12.81M |
| Total Liabilities & Stock Equity | 16.61M | 8.73M | 17.16M | 19.38M |
| Total Common Shares Outstanding | 9.95M | 1.61M | 1.34M | 1.25M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 5.00M | 1.34M | 1.31M | 1.11M |
| Diluted Weighted Shares Outstanding | 5.00M | 1.34M | 1.31M | 1.11M |
| Number of Employees | 22 | 23 | 34 | 33 |
| Number of Part-Time Employees | 5 | 3 | 2 | 3 |
Portfolios with APPY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSUPRATRADE-2709091838
- UserBrahmsian's Debt/Equity Por...
- UserBrahmsian's Financially Sou...
- Userdan vosika Portfolio 1
- Usergame on
- Userdreamerl3oi Portfolio 1
- Useremannn Portfolio 1
Latest APPY Headlines from TheStreet
- 5 Biotech Stocks Under $10 Moving Higher 01.30.13 | 08:01 am
- 5 Breakout Stocks: Must-See Charts 12.21.12 | 05:12 pm
- 5 Stocks Under $10 Set to Soar Higher 09.27.12 | 01:09 pm
- 4 Biotech Stocks Under $10 Making Big Moves 09.11.12 | 02:09 pm
- Biotech Sector Weekly Rewind 11.13.10 | 07:11 am
- Vantage Drilling, First M&F: Volume Movers 07.20.10 | 07:07 am
- AspenBio Finds Fault Afar for Failure 07.20.10 | 06:07 am
- Biotech Stock Mailbag: Spectrum Pharma 06.18.10 | 07:06 am
- Hellenic Telecom, AspenBio Pharma: Midday Volume Plays 06.07.10 | 12:06 pm
- Stock Offerings: Navios Maritime 04.30.10 | 11:04 am
Press Releases for APPY
- Venaxis Announces Pricing Of Offering Of Common Stock And Warrants - PR Newswire 05.23.13 | 07:05 pm
- Venaxis Appoints SomaLogic CMO And Former Pfizer Executive Stephen A. Williams, M.D., Ph.D., To Board Of Directors - PR Newswire 04.18.13 | 04:04 pm
- Venaxis Advances Pivotal U.S. Study And Accelerates European Market Development For APPY1 Blood-based Appendicitis Test - PR Newswire 03.26.13 | 04:03 pm
- Venaxis To Provide Fourth Quarter 2012 Business Update - PR Newswire 03.19.13 | 07:03 am
- Venaxis Secures Additional European Commercial Development Agreements For APPY1 - PR Newswire 03.18.13 | 07:03 am
- Venaxis To Present At 25th Annual ROTH Conference - PR Newswire 03.11.13 | 04:03 pm
- Venaxis Executes First Commercial Development Agreement And Receives Purchase Order From EMELCA Bioscience For Initial EU Launch - PR Newswire 02.07.13 | 07:02 am
- Venaxis Initiates Patient Enrollment For APPY1 Pivotal Study - PR Newswire 01.15.13 | 07:01 am
- Venaxis Obtains CE Mark For APPY1 Appendicitis Test - PR Newswire 01.07.13 | 04:01 pm
- Venaxis Files For CE Mark And Prepares For European Commercialization - PR Newswire 12.21.12 | 07:12 am
Partner Headlines for APPY
- Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD - GuruFocus 07.09.12 | 01:07 pm
- Weekly Market Wrap: Markets SHAKE, Microsoft's NEW Product, Bank Ratings SLASHED - Wall St. Cheat Sheet 06.23.12 | 09:06 am
- P&G SHAVES Profit Outlook and 4 Hot Stocks to Watch - Wall St. Cheat Sheet 06.20.12 | 12:06 pm
- Market Wrap: Oil SPILLS Lower, Microsoft RALLIES, Operation TWIST - Wall St. Cheat Sheet 06.20.12 | 10:06 am
- Morning Market Losers - Benzinga 06.20.12 | 09:06 am
- Ultimate Market Recap: Iffy Adobe Guidance, Jabil Jumps 7% - Wall St. Cheat Sheet 06.20.12 | 08:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.19.12 | 09:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.05.12 | 09:06 am
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test - Benzinga 07.19.10 | 04:07 pm
